Zydus Lifesciences’ subsidiary ZyVet Animal Health has launched FDA-approved generics for urinary incontinence (phenylpropanolamine hydrochloride) and heart failure management (furosemide) in pets. Shares of Zydus Lifesciences Ltd ended lower on Monday (September 15) by 0.84 % at ₹1,036 on the NSE.
